ANDA 77793, held by Aurobindo Pharma USA. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 77793 (Pravastatin Sodium), held by Aurobindo Pharma USA, was first approved by FDA on Jan 15, 2008, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 15, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Feb 24, 2025 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 20, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Feb 11, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 20, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 15, 2015 | Supplement 1Labeling | Approved | None posted |
| Apr 15, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 5, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 3, 2012 | Supplement 4Labeling | Approved | None posted |
| Sep 27, 2011 | Supplement 3Labeling | Approved | None posted |
| Jan 15, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters